The National Drug Administration of China (CNDA) held a meeting on Tuesday, at which it urged for a full investigation into the production procedures and sales chains of all the vaccines produced by Changchun Changsheng Life Sciences.
The move comes as the company stands accused of counterfeiting the vaccine's production data and changing the parameters for the equipment processing the vaccine, an act that violates good pharmaceutical manufacturing practices.
Read more: